[1] |
International Agency for Research on Cancer World Health Organization IARC. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012[J]. Globocan, 2012, 2012: 3-6.
|
[2] |
STRONG V E, WU A W, SELBY L V, et al. Differences in gastric cancer survival between the US and China[J]. J Surg Oncol, 2015, 112(1): 31-37.
doi: 10.1002/jso.23940
pmid: 26175203
|
[3] |
赵群, 李勇, 乔喜, 等. 胃癌组织中HER2蛋白的过表达与临床病理的相关分析[J]. 肿瘤学杂志, 2015, 21(5): 360-364.
|
|
ZHAO Q, LI Y, QIAO X, et al. Correlation between overexpression of HER2 protein and clinicopathology in gastric cancer[J]. J Chin Oncol, 2015, 21(5): 360-364.
|
[4] |
BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697.
doi: 10.1016/S0140-6736(10)61121-X
|
[5] |
KUROKAWA Y, MATSUURA N, KIMURA Y, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer[J]. Gastric Cancer, 2015, 18(4): 691-697.
doi: 10.1007/s10120-014-0430-7
pmid: 25224659
|
[6] |
YAGI S, WAKATSUKI T, YAMAMOTO N, et al. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer[J]. Gastric Cancer, 2019, 22(3): 518-525.
doi: 10.1007/s10120-018-0887-x
pmid: 30328533
|
[7] |
MOTOSHIMA S, YONEMOTO K, KAMEI H, et al. Prognostic implications of HER2 heterogeneity in gastric cancer[J]. Oncotarget, 2018, 9(10): 9262-9272.
doi: 10.18632/oncotarget.24265
pmid: 29507688
|
[8] |
LORDICK F, KANG Y K, CHUNG H C, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial[J]. Lancet Oncol, 2013, 14(6): 490-499.
doi: 10.1016/S1470-2045(13)70102-5
pmid: 23594786
|
[9] |
QAISER T, RAJPOOT N M. Learning where to see: a novel attention model for automated immunohistochemical scoring[J]. IEEE Trans Med Imaging, 2019, 38(11): 2620-2631.
doi: 10.1109/TMI.42
|
[10] |
ZHAO Q, LIAN C H, HUO Z B, et al. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: a multicenter randomized clinical trial[J]. Cancer Med, 2020, 9(16): 5731-5745.
doi: 10.1002/cam4.v9.16
|
[11] |
ZHANG J, TIAN K, DONG P, et al. Microscope based HER2 scoring system[EB/OL]. 2020: arXiv: 2009.06816. https://arxiv.org/abs/2009.06816 [2022-09-01].
|
[12] |
《胃癌HER2检测指南2016版》专家组. 胃癌HER2检测指南(2016版)[J]. 中华病理学杂志, 2016, 45(8): 528-532.
|
|
HER2 Detection Guidelines for Gastric Cancer (2016 edition) Expert Group. HER2 detection guidelines for gastric cancer (2016 edition)[J]. Chin J Pathol, 2016, 45(8): 528-532.
|
[13] |
BARTLEY A N, WASHINGTON M K, COLASACCO C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology[J]. J Clin Oncol, 2017, 35(4): 446-464.
doi: 10.1200/JCO.2016.69.4836
pmid: 28129524
|
[14] |
JI J, SHEN L, LI Z, et al. Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: a randomized phase Ⅲ trial (RESOLVE trial)[J]. Ann Oncol, 2019, 30: v877.
|
[15] |
殷科, 曹永晋. 曲妥珠单抗新辅助化疗表皮生长因子受体2阳性乳腺癌的临床疗效及安全性评价[J]. 中国临床药理学杂志, 2015, 31(9): 725-728.
|
|
YIN K, CAO Y J. Study on efficacy and safety of trastuzumab chemotherapy for the treatment of human epidermal growth factor receptor-2 positive breast cancer[J]. Chin J Clin Pharmocol, 2015, 31(9): 725-728.
|
[16] |
CHUA C, TAN I B, YAMADA Y, et al. Phase Ⅱ study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer[J]. Cancer Chemother Pharmacol, 2015, 76(2): 397-408.
doi: 10.1007/s00280-015-2811-y
|
[17] |
RYU M H, YOO C, KIM J G, et al. Multicenter phase Ⅱ study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer[J]. Eur J Cancer, 2015, 51(4): 482-488.
doi: 10.1016/j.ejca.2014.12.015
|
[18] |
HE Q F, CHEN J H, ZHOU K, et al. Effect of additional trastuzumab in neoadjuvant and adjuvant treatment for patients with resectable HER2-positive gastric cancer[J]. Ann Surg Oncol, 2021, 28(8): 4413-4422.
doi: 10.1245/s10434-020-09405-6
pmid: 33393029
|
[19] |
YUE M, ZHANG J, WANG X R, et al. Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study[J]. Virchows Arch, 2021, 479(3): 443-449.
doi: 10.1007/s00428-021-03154-x
|
[20] |
TUOMINEN V J, TOLONEN T T, ISOLA J. ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry[J]. Histopathology, 2012, 60(5): 758-767.
doi: 10.1111/j.1365-2559.2011.04142.x
pmid: 22296215
|
[21] |
HELIN H O, TUOMINEN V J, YLINEN O, et al. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry[J]. Virchows Arch, 2016, 468(2): 191-198.
doi: 10.1007/s00428-015-1868-7
|
[22] |
HEDNER C, BORG D, NODIN B, et al. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment[J]. J Clin Pathol, 2018, 71(5): 451-462.
doi: 10.1136/jclinpath-2017-204774
pmid: 29138285
|
[23] |
WATSON S, VALIDIRE P, CERVERA P, et al. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study[J]. Ann Oncol, 2013, 24(12): 3035-3039.
doi: 10.1093/annonc/mdt393
pmid: 24114855
|
[24] |
JORDAN N V, BARDIA A, WITTNER B S, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells[J]. Nature, 2016, 537(7618): 102-106.
doi: 10.1038/nature19328
|
[25] |
PUSZTAI L, VIALE G, KELLY C M, et al. Estrogen and HER2 receptor discordance between primary breast cancer and metastasis[J]. Oncol, 2010, 15(11): 1164-1168.
doi: 10.1634/theoncologist.2010-0059
|
[26] |
WETZEL C L, SUTTON T L, GARDINER S, et al. Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes[J]. J Surg Oncol, 2021, 124(8): 1224-1234.
doi: 10.1002/jso.26646
pmid: 34416025
|
[27] |
SEO S, RYU M H, PARK Y S, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)[J]. Gastric Cancer, 2019, 22(3): 527-535.
doi: 10.1007/s10120-018-0891-1
pmid: 30386954
|
[28] |
于观贞, 魏培莲, 陈颖, 等. 人工智能在肿瘤病理诊断和评估中的应用与思考[J]. 第二军医大学学报, 2017, 38(11): 1349-1354.
|
|
YU G Z, WEI P L, CHEN Y, et al. Artificial intelligence in pathological diagnosis and assessment of human solid tumor: application and thinking[J]. Acad J Second Mil Med Univ, 2017, 38(11): 1349-1354.
|